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Summary.-The hypoxic cell radiosensitizing properties of nimorazole have been
investigated in a C3H mammary carcinoma transplanted to the feet of C3D2F1. The
results have been compared with those obtained with misonidazole (MISO) in the
same animal tumour system. For single-dose irradiation in air, nimorazole gives an
enhancement ratio (ER) of , 1.4, independent of the dose of drug administered over
the range 0-1-10 mg/g. MISO yields a similar ER at the O.lmg/g level but, unlike
nimorazole, shows a steep dose-response curve with an ER of 2*2 when given in a
concentration of 1-0 mg/g. No such dose-response relationship is seen with nimora-
zole despite the fact that tumour and plasma concentrations of the 2 drugs have an
identical dose relationship. With irradiation given in5 dailyfractions, nimorazole and
MISO at a dose of 0-3 mg/g per fraction both show an ER of 1-3. The high drug
doses used in single-fraction radiation experiments in animals bear little relation to
those applicable to clinical practice since these would result in unacceptable toxicity.
The results of the present studies are therefore of interest as nimorazole is potentially
less toxic than MISO in humans but demonstrates similar radiosensitizing properties
at clinically relevant dose levels.
WITH THE ESTABLISHMENT of misonida-
zole (MISO) as a potent hypoxic radio-
sensitizer in experimental systems (Adams
et al., 1979b; Denekamp et al., 1982;
Fowler et al., 1976; Overgaard, 1980a),
and the apparent ability to improve the
radiation response in some human tum-
ours (Dische et al., 1979; Kogelnik, 1980;
Overgaard et al., 1982; Phillips et al.,
1981), an increased effort has been made to
discover other compounds with better
hypoxic radiosensitizing abilities but less
clinical toxicity. Extensive use of MISO
in clinical trials has revealed a dose-
limiting peripheral neuropathy which has
prevented the drug being given in suffici-
ent doses (Dische et al., 1979; Kogelnik,
1980; Phillips et al., 1981). In several
clinical studies a dose reduction has been
necessary (Fazekas et al., 1981; Overgaard
et al., 1982), and the current tolerance of
MISO is in the order of 11-12 g/m2 when
given over a 4-week period (Dische et al.,
1979; Kogelnik, 1980; Fazekas et al., 1981;
Overgaard et al., 1982; Phillips et al.,
1981).
The development of new and more
potent sensitizers has focused on drugs
which are expected to be less toxic (e.g.
with reduced lipophilicity and/or reduced
half-life) or on drugs with better hypoxic
radiosensitizing abilities (Adams et al.,
1979a, b; Brown & Lee, 1980; Brown &
Workman, 1980; Dische et al., 1980;
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Workman, 1980; Workman et al., 1980;
Workman & Brown, 1981). Evaluation in
experimental systems has mainly been
undertaken with drug doses which are
higher than those which would be appro-
priate for clinical treatment. However,
comparison and evaluation of new com-
pounds by using high doses in experi-
mental systems are relevant only if the
dose-response relationships for the drugs
are known or expected to be similar.
However, as shown in this paper this may
not necessarily be the case.
The search for drugs with less clinical
toxicity has revealed several unexpected
problems. Thus, the anticipated reduction
in toxicity for drugs with shorter half-lives
has not been confirmed, suggesting that
the mechanism is likely to be more
complex than originally expected
(Coleman et al., 1982; Dische et al., 1980,
1982). Also the toxicological testing of new
compounds has shown that results from
cell cultures and rodents do not always
correlate with experience gained in larger
animals and man. Although some of the
differences can be explained by different
pharmacokinetic parameters, and others
can be eliminated by the use of a more
elaborate experimental design (Conroy et
at., 1982), it still may be difficult to predict
the clinical toxicity on the basis of the
relatively inexpensive in vitro or in vivo
animal studies (Adams et al., 1979b;
Brown et al., 1979; Workman & Brown,
1981).
Rather than concentrating solely on
producing new compounds with better
hypoxic radiosensitizing abilities, it may
be profitable to re-evaluate some of the
nitroimidazoles already used in clinical
practice since these are well known with
regard to human toxicity. This group of
drugs are mainly anti-trichomonal agents
of which metronidazole (Flagyl) was the
first to be tested as a hypoxic radiosensi-
tizer (Fowler et al., 1976; Karim, 1978;
Urtasun et al., 1975), but which has a
sensitizing ability which is probably too
low for widespread clinical utility. Another
similar drug with a toxicity apparently
equal to or less than metronidazole
(Farmitalia, Carlo Erba, unpublished
results) is nimorazole (1-(N-3-ethylmor-
pholine)-5-nitro-imidazole), which is also
widely used as an anti-microbial agent
(Overgaard et al., 1983). Although spor-
adically tested as a hypoxic radiosensitizer
and found to be more potent than
metronidazole (Adams et al., 1979b; Dene-
kamp et al., 1982), relatively little atten-
tion has been paid to this drug. However,
with its apparently low clinical toxicity
together with its potential hypoxic radio-
sensitizing ability we have elected to
reassess nimorazole as a hypoxic radio-
sensitizer in an animal tumour system, and
to compare the results with those obtained
with MISO (Overgaard, 1980a).
MATERIALS AND METHODS
Animal tumour system.-The animal tum-
our system has been previously described in
detail (Overgaard, 1980a, b). Briefly a
C3H/Tif mammary carcinoma was trans-
planted to the right hind foot of 10-12-week-
old male and female C3D2Fl/Bom (C3H/Tif
Y x DBA/2 ,) mice. Treatment was given to
tumours with a volume of 200 mm3, a size
normally obtained about 14 days after
inoculation.
Hypoxic radiosensitizers.-Nimorazole was
supplied by Farmltalia, Carlo Erba, and
MISO by Roche Ltd, Copenhagen. Immedi-
ately before administration the drugs were
dissolved in isotonic saline to a concentration
of 20 mg/ml. This solution was injected i.p.
into non-anaesthetized mice 30 min before the
start ofthe irradiation.
Irradiation.-Tumours were treated with
graded doses of radiation to produce dose-
response data. The treatment was given with
a Muller clinical X-ray machine at a dose rate
of 1 9 Gy/min (factors: 250 kV, 15 mA, 2 mm
Al filtration, 1 1 mm CuHVL, SSD 40 cm).
Unanaesthetized animals were placed in a
lucite jig with the tumour-bearing leg closely
fixed with tape but without impairing the
blood flow to the foot. Radiation was given to
tumours immersed in a water bath at room
temperature, to secure the homogeneity ofthe
radiation dose. The remaining part of the
animal was shielded with lead. Dosimetry was
performed with a Dosimentor SN4 dosimeter.
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Evaluation of results.-The animals were
followed for up to 120 days after treatment.
The response to treatment was measured as
the radiation dose which would on average be
expected to control 50% of the treated
tumours (TCD5o) at 120 days. The TCD50
values were calculated by logit analysis (Suit
et al., 1965) from assays containing 40-70
animals allocated into 5-8 dose groups.
The effect on the radiation response of any
additional treatment was calculated as the
"enhancement ratio" (ER) which is the
radiation dose required to obtain a given end
point (TCD5o) with radiation alone relative to
the radiation dose needed to obtain the same
response with the combined treatment
LD50 determination was based on the acute
lethality within 2 days in experiments where
graded single doses of drugs were given to
groups ofanimals.
Measurement ofdrug concentrations.-Blood
samples were obtained by open-heart punc-
ture after killing the mice by cervical
dislocation, Plasmaconcentrations were meas-
ured by reversed-phase high-pressure liquid
chromatography (HPLC) (Overgaard et al.,
1983) by injecting 25 ,lI of the sample in a
nucleosil 10 Fm C18 column at a flow of 2
ml/min.
Nimorazole was analysed using 60%/ meth-
anol in a 20mM phosphate buffer, pH 6-5, as
mobile phase and phenytoin as internal
standard. MISO was determined with 25%
methanol in water as mobile phase and with
RO-07-0269 as internal standard. The UV
absorption was measured at 313 nm.
Tumour concentrations were measured in
specimens removed and weighed in toto. A
known amount of internal standard was
added together with methanol to a 5-fold
increase in volume. After mixing with a
rotating knife, the sample was centrifuged at
3000g for 10 min. The supernatant was
removed and the solvent evaporated at 37°C
under a stream of dry nitrogen. The dried
residue was redissolved in 500 ,lI methanol
and estimated similar to the plasma samples.
Untreated tumours to which a known amount
of drug was added showed that during this
procedure the recovery of sensitizer was
>90%. All plasma and tumourmeasurements
were performed in duplicate.
RESULTS
Acute toxicity
The acute toxicity measured as the
LD50 was found to be 1P8 mg/g for MISO
and 1 6 mg/g for nimorazole (Table I).
Thus the latter seems to be a slightly more
toxic substance in this strain of mice.
Animals surviving 2 days appeared
healthy and showed no later behaviour
which could be attributed to toxicity. No
sex variation was observed for any of the
drugs.
Sensitizing effect
The relationship between sensitizing
effect and given dose of the 2 drugs was
first studied in a single-treatment schedule
in which the drugs were given 30 min
before irradiation. Table II shows the ERs
TABLE I.-Some physicochemical and toxicological properties
Parameter
MIol. wt
Octanolv/water
partition pH 7. 4c
One-electron
reduction potential (E71)c
Solubility in
isotone saline 220C
LD5o, 2 days i.p. injection
in C3D2F1 mice
Aerobic toxicityb, c
in V79 cells
Units
g/mol
mV
mg/ml
mg/g
mmol/l
Nimorazole
226 - 2
1 40
-457
30
1 *61
(1* 55-1 * 67)a
75
a 95% confidence limits.
b Dose to reduce survival to 10-2 in 5 h.
c Data from Adams et al. (1979a, b) and Denekamp et al. (1982).
Misonidazole
201 -2
0 43
-389
> 17
1 *83
(1-66-2.02)
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TABLE II.-CoMparison ofthe effect ofMISO and nimorazole on the response of single-
dose radiation
Dose of
sensitizera
(mg/g)
None
(radiation
alone)
MISO
t ~~~~A_
TCD50
(Gy) ER
56-2
(54.5-57.9)
Nimorazole
TCD50
(Gy) ER
56-2
(54-5-57-9)
1.0 25-7 2-18 37-6
(23-5-28-1) (2.03-2-35) (33 3-42 5)
0-8 - - 38-2
(33 0-44- 1)
0 5 34-2 1-65 39 0
(30.4-38.2) (1 50-180) (354-42 9)
0-3 35-9 1-56 39 7
(31-8-39-3) (1 46-167) (34 4-46-6)
0-1 40 0 1*41 41-4
(37 0-43 2) (1-32-1-50) (37-3-46.1)
a Given 30 min before radiation.
Numbers in parentheses represent 95% confidence limits.
1-49
(1 40-159)
1-47
(1-32-1-63)
1 -44
(1.34-1-55)
1 -42
(1 -31-1 -53)
1 -36
(1.24-1.48)
ER MISO
ER nimorazole
1-46
(1 -18-1 -81)
1.15
(0-89-1 -48)
1-10
(0-87-1-38)
1-04
(0-82-1.32)
CH2CH2NJ CH2CH(OH)CH20CH3
N2NNN
N N
Nimorazole Misonidazolc
FIG. 1.-Structural formula for nimorazole
and MISO.
for nimorazole and MISO when given in
doses between 0.1 and 1-0 mg/g and
reveals an apparent difference in their
dose-response relationships. MISO demon-
strates a well-defined relationship between
given dose and ER such that anincrease in
dose results in a similar increase in
enhancement. This relationship can be
expressed as a linear-linear function
between dose in mg/g and ER with a slope
of 0-86 + 0 09. A similar dose-response
relationship was not apparent for nimor-
azole, although a slight increase in ER
may appear with increasing doses. How-
ever, none ofthe ERs observed at doses of
0.1-1.0 mg/g with nimorazole were statis-
tically significantly different from each
other.
The difference in dose response between
the 2 drugs was most obvious at high
doses. After doses of 1 0 mg/g the effect of
MISO was significantly better than that of
nimorazole. Such a difference could not,
however, be demonstrated at lower doses
and, in the high dose range 0-1-0 3 mg/g,
the drugs seem to be equal in sensitizing
ability.
Since the difference in dose-response
relationship could be a consequence of
different pharmacokinetics, the plasma
and tumour concentration were measured
at the time ofirradiation (i.e. 30 min after
administration). As shown in Fig. 2, both
drugs had a well-defined dose-response
relationship between plasma and tumour
concentration and given dose. Further-
more, these values seemed to be equal for
the 2 drugs. Thus, the lack of dose-
response relationship could not be
explained as a function of different drug
distribution and, as shown in Fig. 3, the
difference in dose-response relationship
between MISO and nimorazole was also
observed when the ERs were plotted
against tumour drug concentration. Again,
low values of both drugs seemed to give
similar ERs, whereas after larger doses
MISO exhibited a significantly higher
degree of sensitization than nimorazole.
In order to make the experimental
observations more relevant to clinical
treatment, the effect offractionated treat-
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FIG. 2. Relationship between given drug dose and concentrations in plasma and tumour mcasured 30
mmn after i.p. injection. MISO: tumour/plasma ratio=0-51; 0, plasma slope=0-825, r=0 9888;
0, tumour slope=0-418, r=0-9778. Nimorazole: tumour/plasma ratio=0 50; O, plasma slope=
0-769, r=0-9981; *, tumour slope=0-384, r=0-9915.
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FIG. 3.-Relationship between tumour con-
centration and enhancement ratio.
TABLE III.-Radiosensitizing effect in
fractionated treatment
TCD50
Treatment (Gy) ER
Five daily fractions of 62-1
radiation alone (control) (57 7-66 * 9)
Five fractions ofradiation 47 - 0 1 32
0 3 mg/g MISO before (43-7-50*5) (1*10-1*58)
each fraction
Five fractions ofradiation 49 1 1 26
0 3 mg/g nimorazole (43 * 7-55 * 2) (1*01-1 58)
before each fraction
Numbers in parentheses represent 95% confidence
limits.
ment was studied by giving 5 fractions of
irradiation at daily intervals with drug
doses of 0 3 mg/g 30 min before each
radiation fraction. Such treatment gave
almost identical enhancement values for
both drugs indicating that also after
fractionated treatment the effect of the 2
sensitizers appears to be similarwhen rela-
tively smalldrugdoses areused (Table III).
Drug cytotoxicity
Finally, the potential hypoxic cell
TABLE IV.-Potential cytotoxic effect of
MISO and nimorazole
Treatment
Radiation alone
MISO
1 *0 mg/g after
radiation
Nimorazole
I 0 mg/g after
radiation
TCD50
(Gy)
56-2
(54.5-57-9)
55-3
(50-4-60*7)
ER
1 *02
(0*96-1*06)
56 0 1-00
(50*4-62-4) (0*94-1*08)
Numbers in parentlheses represent 95% confidence
limits.
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cytotoxicity was estimated by giving the
drugs immediately after a single dose of
irradiation. As seen in Table IV, none of
the drugs given in single doses of 1 mg/g
was able significantly to alter the TCD50
values when compared to irradiation
alone. An important drug cytotoxicity
against hypoxic tumour cells seems there-
fore not to occur after such treatment in
the present tumour system.
I)ISCUSSION
The present study has shown that
nimorazole enhances the radiation re-
sponse in an experimental mammary
carcinoma but with an unusual lack of
dose-response relationship over a wide
dose range. This contrasts with MISO,
which has a relatively steep dose-response
relationship with ERs in the same range as
those observed in similar or other tumour
models (Denekamp et al., 1982; Fowler et
al., 1976). This lack of dose-response
relationship may be the reason why
nimorazole has not previously been re-
garded as a hypoxic sensitizer with clinical
potential. However, in the dose range
which is relevant to clinical treatment
schedules (. 0 3 mg/g per fraction,
depending on fractionation scheme) nimor-
azole produces the same enhancement as
MISO. The difference between the 2 drugs
is only significant at high concentrations,
but these have little interest for clinical
radiotherapy since the doses required
cannot be achieved in humans without
excessive toxicity. The flat dose-response
curve may also explain why nimorazole
has not been considered to be an effective
sensitizer, since a common in vitro screen-
ing procedure is to establish the dose
required to produce an ER of 1 6 (Adams
et al., 1979b). A similar plateau of the
dose-responsecurveobservedinthepresent
studyhas alsobeenreportedusingV79 cells
in vitro (Adams et al., 1979a; Midander &
Littbrand, submitted for publication).
The difference in dose-response relation-
ship could not be explained by different
tumour drug concentrations, although the
2 drugs differ in pharmacokinetics and in
lipophilicity. MISO is less lipophilic and
has a shorter half-life in mice than
nimorazole. However, neither the differ-
ence in lipophilicity nor in half-life seems
to influence the tumour/plasma ratio in
mice (Workman, 1980; Workman &
Brown, 1981). The difference in lipophil-
icity means a greater metabolic degrada-
tion of nimorazole (Giraldi et al., 1971),
whereas MISO is excreted to a higher
degree unmetabolized in the urine (Work-
man, 1980). The possibility exists that the
metabolism of nimorazole results in sec-
ondary products which may also act as
hypoxic radiosensitizers and that these in
turn may contribute to the overall ER.
However, preliminary pharmacokinetic
analyses of these products have shown
that they are not present in significant
amounts in either plasma or tumour at the
time ofirradiation.
Both the plasma concentration, the
tumour/plasma ratio, the LD50 values and
the ERs obtained with MISO are similar to
those observed in otherstudies (Denekamp
et al., 1982; Fowler et al., 1976; Rofstad &
Brustad, 1978; Workman, 1979). This
indicates that the present experimental
system is valid for this kind ofexperiment,
and makes the results directly comparable
with those ofothers.
The difference between the toxicity of
the 2 drugs which is observed in different
experimental systems is a typical example
oftheproblems relating to toxicity evalua-
tion of potential hypoxic radiosensitizers.
Thus, nimorazole is probably (though not
statistically) more toxic in mice with
slightly smaller LD50 values. However,
MISO has considerably more aerobic
toxicity in V79 cells (Adams et al.,
1979b). Likewise, the LD50 values in
rats are apparently smaller for MISO than
for nimorazole (1680 and 3180 mg/kg
respectively after oral administration).
Furthermore, comparable data indicate
that nimorazole has considerably less
acute or chronic toxicity in dogs, and
nimorazole seems to be even less toxic in
dogs than metronidazole (Roche, unpub-
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lished data; Farmltalia, Carlo Erba,
unpublished data). In humans nimorazole
has been given in doses up to 25 g in 10
days without causing peripheral neuro-
pathy or other severe side effects
(Overgaard et al., 1983). Thus nimorazole
seems to be considerably better tolerated
than MISO, and on the basis of large-
animal toxicity it may be tolerated as well
as metronidazole (Flagyl) which can be
given in daily doses of 6 g/m2 and in total
doses up to 100 g (Kapp et al., 1982;
Karim, 1978; Urtasun et al., 1975).
Therefore it is likely that nimorazole could
be given in normal radiation fractionation
schedules in doses corresponding to those
necessary to produce ERs of 1-4 in the
present tumour after single-dose radiation
in air.
Evidently nimorazole with its flat dose-
response curve does not promise a greater
radiosensitizing effect than MISO, even
when given in higher doses. However, if
the lack of significant toxicity can be
established, it might be a more acceptable
drug with a better therapeutic ratio in
clinical treatment. Further studies to
explore the potential of nimorazole as a
hypoxic radiosensitizer in clinical radio-
therapy have therefore been started
(Overgaard et al., 1983).
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